About Nightstar Therapeutics (NASDAQ:NITE)
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NITE
CUSIPN/A
Phone646-522-8445
Debt
Debt-to-Equity RatioN/A
Current Ratio14.38%
Quick Ratio14.38%
Price-To-Earnings
Trailing P/E Ratio-8.80
Forward P/E Ratio-7.88
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.48 per share
Price / Book3.20
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees23
Outstanding Shares28,100,000
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
When is Nightstar Therapeutics' next earnings date?
What price target have analysts set for NITE?
6 brokerages have issued 12 month price objectives for Nightstar Therapeutics' stock. Their predictions range from $20.00 to $40.00. On average, they anticipate Nightstar Therapeutics' share price to reach $28.50 in the next year. View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (4/7/2018)
- 2. Mizuho analysts commented, "We are less concerned about financial performance than progress in the pipeline. In our view, Nightstar has the most comprehensive data in Choroideremia (CHM) in the gene therapy space. The phase 3 STAR trial of NSR-REP1 in CHM was recently initiated and could be adequate to support a BLA filing in 2020." (4/5/2018)
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX) and Jounce Therapeutics (JNCE).
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 61)
- Mr. Senthil Sundaram, CFO & Principal Accounting Officer (Age 40)
- Dr. Gregory Robinson Ph.D., Chief Scientific Officer (Age 59)
- Mr. Aniz Girach, Chief Medical Officer
- Dr. Tuyen Ong M.D., MRCOphth, MBA, Exec. VP & Chief Devel. Officer (Age 43)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
When did the company's lock-up period expire?
Nightstar Therapeutics' lock-up period expired on Tuesday, March 27th. Nightstar Therapeutics had issued 5,360,000 shares in its public offering on September 28th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Has Nightstar Therapeutics been receiving favorable news coverage?
News articles about NITE stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also gave headlines about the company an impact score of 47.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Nightstar Therapeutics?
Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of NITE stock can currently be purchased for approximately $14.34.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $406.33 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe.
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Nightstar Therapeutics (NASDAQ:NITE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Nightstar Therapeutics in the last 12 months. Their average twelve-month price target is $28.50, suggesting that the stock has a possible upside of 98.74%. The high price target for NITE is $40.00 and the low price target for NITE is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.50 | $28.50 | $30.20 | $24.75 |
| Price Target Upside: | 98.74% upside | 96.82% upside | 106.71% upside | N/A |
Nightstar Therapeutics (NASDAQ:NITE) Consensus Price Target History
Nightstar Therapeutics (NASDAQ:NITE) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Nightstar Therapeutics (NASDAQ:NITE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Nightstar Therapeutics (NASDAQ NITE) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 29.06%
Nightstar Therapeutics (NASDAQ NITE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Nightstar Therapeutics (NASDAQ NITE) News Headlines
| Source: |
|
Nightstar Therapeutics (NASDAQ:NITE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Nightstar Therapeutics (NASDAQ:NITE) Income Statement, Balance Sheet and Cash Flow Statement
Nightstar Therapeutics (NASDAQ NITE) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
